Clinical Trial Update: Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock [Phase 4]

View source ↗

Summary

Phase 4 trial update on drotrecogin alfa (activated) examines hemodynamic and perfusion responses in patients with septic shock; results were posted in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Xigran (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis, Septic Shock | Phase 4 | Status: COMPLETED | Results posted: 2009-08-17